- Home
- SPFI vs REPL Comparison
SPFI vs REPL Comparison
Compare SPFI & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPFI
- REPL
- Stock Information
- Founded
- SPFI 1941
- REPL 2015
- Country
- SPFI United States
- REPL United States
- Employees
- SPFI N/A
- REPL N/A
- Industry
- SPFI Major Banks
- REPL Biotechnology: Pharmaceutical Preparations
- Sector
- SPFI Finance
- REPL Health Care
- Exchange
- SPFI Nasdaq
- REPL Nasdaq
- Market Cap
- SPFI 662.8M
- REPL 547.0M
- IPO Year
- SPFI 2019
- REPL 2018
- Fundamental
- Price
- SPFI $37.67
- REPL $8.43
- Analyst Decision
- SPFI Buy
- REPL Hold
- Analyst Count
- SPFI 3
- REPL 9
- Target Price
- SPFI $41.67
- REPL $6.67
- AVG Volume (30 Days)
- SPFI 44.8K
- REPL 3.5M
- Earning Date
- SPFI 10-23-2025
- REPL 11-11-2025
- Dividend Yield
- SPFI 1.73%
- REPL N/A
- EPS Growth
- SPFI 19.09
- REPL N/A
- EPS
- SPFI 3.20
- REPL N/A
- Revenue
- SPFI $199,001,000.00
- REPL N/A
- Revenue This Year
- SPFI $13.41
- REPL N/A
- Revenue Next Year
- SPFI $6.10
- REPL N/A
- P/E Ratio
- SPFI $11.57
- REPL N/A
- Revenue Growth
- SPFI 7.49
- REPL N/A
- 52 Week Low
- SPFI $30.01
- REPL $2.68
- 52 Week High
- SPFI $42.38
- REPL $17.00
- Technical
- Relative Strength Index (RSI)
- SPFI 44.39
- REPL 73.24
- Support Level
- SPFI $36.50
- REPL $4.49
- Resistance Level
- SPFI $39.41
- REPL $10.29
- Average True Range (ATR)
- SPFI 1.16
- REPL 0.45
- MACD
- SPFI -0.08
- REPL 0.47
- Stochastic Oscillator
- SPFI 38.01
- REPL 69.43
About SPFI South Plains Financial Inc.
South Plains Financial Inc operates as a bank holding company. The company provides a wide range of commercial and consumer financial services to small and medium-sized businesses and individuals. The principal business activities include commercial and retail banking, along with insurance, investment, trust, and mortgage services. The company has one reportable segment: banking.
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.